| Description | Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM). It can lower glucose in an animal model of type 2 diabetes and shows excellent developability properties. |
| Target activity | ASBT:42 ± 3 nM |
| Synonyms | GSK2330672, Iinerixibat |
| molecular weight | 546.68 |
| Molecular formula | C28H38N2O7S |
| CAS | 1345982-69-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 21.5 mg/mL |
| References | 1. Nunez DJ, et al. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin. Diabetes Obes Metab. 2016 Jul;18(7):654-62. 2. Wu Y, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. |